Abstract Background: Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality worldwide. However, it is often under diagnosed and under treated, resulting in underestimation of the burden of this disease. COPD is defined as a preventable and treatable disease with some significant extra pulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
Introduction
COPD is a common preventable and treatable disease is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases [1] .
Exacerbations and co morbidities contribute to the overall severity in individual patients. Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality worldwide. However, it is often under diagnosed and under treated, resulting in underestimation of the burden of this disease [2] .
COPD is defined as a preventable and treatable disease with some significant extra pulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases [3] .
COPD is a disease state characterized by airflow limitation that is not fully reversible, the airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases and associated with systemic manifestations [4] .
The burden of COPD is underestimated because it is not usually recognized and diagnosed until it is clinically apparent and moderately advanced. Prevalence, morbidity, and mortality in Egypt are still lacking and have to be estimated, however, COPD is a significant health problem in both men and women. The economic costs of COPD are high and will continue to rise in direct relation to the ever-aging population, the increasing prevalence of the disease, and the cost of new and existing medical and public health interventions [1] .
Morbidity measures traditionally include physician visits, emergency department visits, and hospitalizations. Although CORD databases for these outcome parameters are less readily available and usually less reliable than mortality databases, the limited data available indicate that morbidity due to CORD increases with age [5, 6] . Morbidity from COPD may be affected by other co morbid chronic conditions (e.g. cardiovascular disease, musculoskeletal impairment, and diabetes mellitus) that are related to CORD and may have an impact on the patient's health status, as well as interfere with COPD management.
The age-adjusted death rates for COPD by race and sex in the US from 1960 to 1996 revealed that COPD death rates are very low among people under age 45, but then increase with age, and COPD becomes the fourth or fifth leading cause of death among those over 45 years, a pattern that reflects the cumulative effect of cigarette smoking [7] .
Observed increases in mortality and morbidity appear to be related to past trends in cigarette smoking. Part of the rise in morbidity and mortality may be due to increasing numbers of people living longer, the increases in morbidity and mortality are particularly staking among older people who continue to smoke [8] .
Patients and methods
This was a retrospective study that was based upon collecting the data of all COPD patients who were admitted at Maamoura Chest Hospital during the period from 2009 till 2012. The data included the following:
(1) Personal data (age, sex, occupation, residence, special habits {smoking and addiction}. 
Statistical analysis of the data
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. Qualitative data were described using number and percent. Quantitative data were described using mean, standard deviation minimum and maximum. Comparison between different groups regarding categorical variables was tested using Chi-square test. Significance test results are quoted as two-tailed probabilities. Significance of the obtained results was judged at the 5% level. Table 1 shows that 77.3% of the patients' age ranged between 35 and 70 years, 11.4% of them were <35 years and 11.3% were >70 years. Regarding the sex of the patients, 97.4% of them were males and 2.6% were females. As regards the residence, 75.6% of the patients lived in urban areas and 24.4% lived in rural areas. By looking at the occupation, 58.7% were not working, 38.9% were manual workers and 2.4% were office workers (see Fig. 1 ). Table 2 shows that 47.1% of the manual workers were exposed to inorganic dust (22% of them were exposed to silica dust, 11% were exposed to asbestos fibers and 14.1% were exposed to coal dust), 11.1% of them were exposed to organic dust and 41.8% were exposed to other chemicals and irritant gases. Table 3 shows that 12.8% of the patients were addicts and 87.2% of them were none. As regards the addict group, 57.1% of them were addict to cannabis, 19.1% of them were intravenous addicts and 23.8% were addict to tramadol. Table 4 shows that 86.5% of the patients were smokers and 13.5% were non smokers. In the smoking group, 19.2% were mild smokers, 38.4% were moderate smokers and 42.4% were heavy smokers according to smoking index with a mean ± SD 21.89 ± 15.92. Table 5 shows that 40.6% of the cases were complaining of dyspnea Grade III, 38.4% of them were complaining of dyspnea Grade II, while 14.8% were complaining of dyspnea Grade I and 6.2% were complaining of dyspnea Grade VI. In addition, 77.3% of the patients were complaining of productive cough and 22.7% were complaining of dry cough. Also, 86.7% of the patients were complaining of wheezes and 13.3% of the cases had silent chest. Table 6 shows that frequency of exacerbation/year was 4 episodes/year in 29% of the patients, 5 episodes/year in 26.1% of the patients, 3 episodes/year in 11.8% of the patients, 2 episodes/year in 10.8% of the patients, once/year in 9.4% of the patients, 8 episodes/year in 5.4% of the patients, 6 episodes/year in 4.5% of the patients, 10 episodes/year in 2.3% of the patients and 12 episodes/year in 0.7% of the patients respectively. Table 7 shows that the most common co morbidities in the patients were respiratory infections (53.9%), heart failure (44.5%), IHD (37.9%), AF (30.5%), HTN (26.9%) and DM (19.5%) respectively. Table 8 shows that the most common complications in the studied patients were corpulmonale in 44.5% of cases, respiratory failure type 2 in 16.6% of cases, secondary polycythemia in 15.1% of cases, pneumothorax in 10.7% of cases, lung cancer in 12.2% of cases and complications due to medications Figure 1 Mortality rate among the studied cases. Table 9 shows that 31.6% of the studied cases were admitted to the ICU and 68.4% of them were not. Table 10 shows that there was a highly significant relation between the presence of respiratory failure type II, corpulmonale and secondary polycythemia and the need for ICU admission, but this relation was not significant as regards the presence of pneumothorax and lung cancer. Table 11 shows that the studied cases had FEV1 ranging from 28.0% to 67.0% with a mean of 45.75 ± 8.19 . Only 89.2% of the cases had done PFT and 10.8% did not perform PFT. Table 12 shows that there was a significant relation between the smoking index and the increase in the level of obstruction i.e. disease severity (expressed by decreased FEV1/FVC ratio). Also, there was a highly significant inverse correlation between smoking index and FEV1/FVC%, i.e. as the smoking index increases, the FEV1/FVC% decreases. Table 13 shows that 93.7% of the studied cases used inhaled corticosteroids (ICS), 90.9% used long acting B2 agonist (LABA), 90.8% used short acting B2 agonist (SABA), 97.2% used mucolytics, 90.8% used broad spectrum antibiotics, 88.5% used anticholinergics, 77.9% used theophylline and 51.7% used systemic corticosteroids. Table 14 shows that 55.5% of the studied cases received pulmonary rehabilitation, 19.4% were put on CPAP, 83.6% received O 2 therapy, 11.9% were put on invasive mechanical ventilation and 2.1% received pneumococcal vaccine. Table 15 shows that there was a highly significant relation between the presence of respiratory failure type 2, corpulmonale, pneumothorax, lung cancer and polycythemia as complications of COPD and the need for O 2 therapy. Table 16 shows that there was a highly significant relation between the presence of respiratory failure type II and the need for CPAP, but this relation was not significant with the presence of other complications. Table 17 shows that there was no significant relation between the presence of the different complications of COPD and the need for invasive mechanical ventilation. Table 18 shows that the overall mortality rate among the studied cases was 5.7%. Table 19 shows that the mortality rate among the patients who received O 2 therapy was 8.5%. Table 20 shows that the mortality rate among the patients who were put on CPAP was 85.1%. Table 21 shows that the mortality rate among the patients who were put on invasive mechanical ventilation was 63.8%. Table 22 shows that the mortality rate among the patients who were admitted to the ICU was 44.7%. 
Results

Discussion
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease, characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and co morbidities contribute to the overall severity in individual patients [1] . Age is often listed as a risk factor for COPD. It is unclear if healthy aging as such leads to COPD or if age reflects the sum of cumulative exposures throughout life. In the present study, COPD was most common in the patients whose age ranged between 35 and 70 years (77.3%), 11.4% of the patients were under the age of 35 years and 11.3% of the patients were above the age of 70 years. In accordance with this result, Hnizdo et al. [9] found that patients aged 30-75 years estimated the major fraction of COPD. Also, Higgins [10] reported that a diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally smoking). Fletcher et al. [11] reported that while COPD is known to significantly impact older age groups, it also affects people of working age. Recent data report that 26% of people with COPD in the UK aged 45-65 gave up work because of their condition, and of those having COPD remaining in work, 22 .9% felt that it lowered their productivity. Different results concluded by American Lung Association [12] found that COPD is not common among populations under 45 years of age. Halbert et al. [13] found that the majority of the studies concerned patients over 40 years of age, in particular those aged between 40 and 64 years. The prevalence of COPD increases with age, with a fivefold increased risk for those aged over 65 yrs compared with patients aged less than 40 years.
As regards sex of the patients in our study, COPD was more prevalent in males than in females; it included 97.4% males and 2.6% female. This result is supported by the statement of National Heart, Lung and Blood Institute [14] which informed that COPD prevalence and mortality were greater among men than among women. In addition, Bourke [15] reported that there is a higher prevalence of COPD in men than in women, where there is an increased incidence of manual labor such as mining and welding, which carry an increased risk of COPD. On the contrary to this result; Bill et al. [16] found that COPD was more common in women than in men. Hogg et al. [17] described that studies have shown that women with COPD generally report more breathlessness, depression and frequent exacerbations than men, even when their FEV1 is the same. However; Mannino et al. [18] showed that the prevalence of the disease is now almost equal in men and women, probably reflecting the changing patterns of tobacco smoking. Also, Viegi et al. [19] addressed the important issue of a remarkably high incidence of COPD in the youngest women, which suggests a further shift toward females in the sex distribution of COPD. In conclusion, these recent data from several large studies suggest that females may in fact be more susceptible to the effects of tobacco than males. These studies differ according to the number and place of subjects. More data are needed to verify this. The importance of these new data, however, is that male sex is now clearly not a risk factor for COPD.
As regards the socioeconomic status, there is a higher incidence of COPD in patients of lower socioeconomic status, particularly those living in urban rather than in rural areas. In the present study, it was found that among the studied cases, 75.6% lived in urban areas and 24.4% lived in rural areas. This pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, infections, or other factors that are related to low socioeconomic status. This result matches with that reported by Prescott et al. [20] that stated that poverty is clearly a risk factor for COPD and there is strong evidence that the risk of developing COPD is inversely related to socioeconomic status. They concluded that poverty is an important surrogate of COPD. There is a higher incidence of COPD in patients of lower socioeconomic status, particularly those living in urban rather than rural areas.
Tobacco smoking is the main risk factor for COPD. In our study it was found that studied cases included 86.5% smokers and13.5% non smokers. This result matches with that reported by Agusti et al. [21] , which found that Tobacco smoking is by far the most important risk factor for COPD worldwide, Siafakas et al. [22] also reported that smoking is the main risk factor for the development of COPD. Overall, tobacco smoking accounts for as much as 90% of COPD risk.
There is a direct relationship between the amount of cigarettes and the number of years smoked, which is quantized in terms of 'pack years'. The formula used to determine this is Number of cigarettes smoked per day · number of years smoked/20 to form pack year index. In this current study, according to this index, it was found that 19.1% of smokers were mild smokers, 38.4% were moderate smokers and 42.4% were heavy smokers, with a mean 21.89 ± 15.92. Similarly, American Collage of Chest Physicians/American Thoracic Society/European Thoracic Society guidelines found that the value of patient history and physical examination was addressed in the 2011 update for diagnosis and management of stable COPD. According to the 2011 guidelines, a history of more than 40 pack-year of smoking was the best single predictor of airflow obstruction.
In the present study, it was found that there is a significant relation between smoking index and the degree of disease severity or level of decline of pulmonary functions. There was a highly significant inverse correlation found between smoking in pack years and FEV1/FVC%, i.e. as the smoking index increases, the FEV1/FVC% decreases. This result is similar to those of early studies conducted by Fletcher et al. [23] that stated that cigarette smoking accelerates the rate of decline in FEV1, but it is thought that this may be greater in the presence of airway hyper-responsiveness. Also, this result agrees with those of the study of Tonnesen et al. [24] , who reported that people who smoke have an increased annual decline in FEV1:the physiologic normal decline in FEV1 is estimated to be 20-30 ml/y, but the rate of decline in COPD patients is generally 60 ml/y or greater. Nagelmann et al. [25] found that lung function deviation and lung structural changes are present in people who smoke cigarettes before the clinical signs of airways obstruction reveal them. These changes can be detected by body plethysmography and diffusing capacity measurement with routine spirometry.
As regards the occupation in this current study, it was found that 47.1% of COPD patients were manual workers who were exposed to inorganic dust, while 11.1% of them were exposed to organic dust and 41.8% of them were exposed to other chemicals and irritant gases. Among the group of manual workers who were exposed to inorganic dust, 22% of them were exposed to silica dust, 11% of them were exposed to cotton dust and 14.1% of them were exposed to coal dust. This result coincides with observations of Burge [26] , that recorded accelerated decline in lung function among plastics workers exposed to toluene diisocyanate and in carding room workers in cotton mills. Exposure to cadmium, a heavy metal, and welding fumes has been recognized as a cause of emphysema since the 1950s. Hnizdo et al. [27] found an increased number of cases of chronic bronchitis in coal and gold miners, long-term exposures to low levels of silica may lead to the development of chronic bronchitis and emphysema. Bill et al. [16] found that occupational dusts; organic and inorganic; are attributable risks in 15% of American population. Automobile-drivers, vehicular mechanics, chlorinated organic compounds dyes, explosives, rubber products, metal etching, plastics, ammonia exposure in refrigeration and petroleum refining, grain dust and funguses in farmers, textile mill manufacturing, leather manufacturing, food products manufacturing and sales, beauty care workers and welders in automotive industries. Also, this result is consistent with the results of Hendrick [28] , who reported that shipyard welders and caulkers are also known to have an increased risk of developing COPD as well as those working in the construction industries that are exposed to cement dust. Different results had been reported by eauWyatt [29] , who found that COPD is the most common respiratory syndrome in agricultural workers, and there is a 10% prevalence of COPD among farm workers.
Regarding addiction in the present study, it included 12.8%addicts and 87.2% non addicts. Also, it was found that 57.1% of the addicted persons were addicted to cannabis including marijuana, 19% of them was intravenous addicts and 23.8% addicts to tramadol. In accordance with this finding, Salvi and Barnes [30] found that other types of tobacco e.g. pipe, cigar, water pipes and marijuana are also risk factors for COPD. Nagelmann et al. [25] stated that emphysema occurs in approximately 2% of persons who use intravenous drugs. This is attributed to pulmonary vascular damage that results from insoluble filler (e.g. cornstarch, cotton fibers, cellulose and talc) that contained methadone or methylphenidate. Lamprecht et al. [31] found that in association with IV use of cocaine or heroin; emphysema occurs predominantly in the upper lobes. In contrast, methadone and methylphenidate injections are associated with basilar and panacinar emphysema. Vilagoftis et al. [32] said that it is worth mentioning that marijuana (cannabis) may be a major cause of COPD for the future. Although marijuana cigarettes are not smoked as often as nicotine cigarettes, marijuana smoking involves a larger volume a longer breath hold. The result of the present study disagrees with those of Tashkin et al. [33] ; who had done various studies suggesting that marijuana smoking may not affect an accelerated reduction in FEV1. However, a study by Johnson et al. [34] reported a bullous lung disease in young adults who had smoked marijuana.
In this current study, it was found that frequency of exacerbation/year in COPD patients was 4 episodes/year in 29% of patients, 5 episodes/year in 26.1% of patients, 3 episodes/year in 11.8% of patients, 2 episodes/year in 10.8% of patients, once/year in 9.4% of patients, 8 episodes/year in 5.4% of patients, 6 episodes/year in 4.5% of patients 10 episodes/year in 2.3% of patients and 12 episodes/year in 0.7% of patients respectively. Different results had been reported by Davis et al. [35] and Barnett [36] showed that the average district general hospital will receive between 1000 and 1200 admissions a year, with a mean stay of 10.3 days.
In this current study, as regards cough, it was found that 77.3% of the patients were complaining of productive cough and 22.7% complaining of dry cough. These findings were similar to those of Georgopoulas and Anthonisen [37] , who found that chronic cough is usually productive and is very often discounted as it is considered an expected consequence of smoking. Also, this matches with that reported by Burrows et al. [38] , who stated that sputum initially occurs in the morning but later will be present all day long. It is usually tenacious. The chronic cough in COPD may be unproductive. Robin et al. [39] showed that one of the first signs of COPD is a persistent productive cough that is often worse in the morning. Contrary to this result, Anthonisen [40] found that in some cases of COPD, significant airflow limitation may develop without the presence of a cough.
In this current study, it was found that 40.6% of the cases were complaining of dyspnea Grade III, 38.4% Grade II, 14.8% Grade I and 6.2% Grade VI. In accordance with our study, Simon et al. [41] and Elliott et al. [42] reported that typical COPD patients describe their dyspnea as a sense of increased effort to breathe, heaviness, air hunger, or gasping. However, the terms used to describe dyspnea vary both by individual and by culture. In a study done by Graham Barr et al. [43] among 1003 patients with COPD, 61%reported moderate or severe dyspnea. Different results reported by Nishimura et al. [44] , who studied 183 COPD patients. They found that 67 patients (36%) were classified with Grade II, 87 patients (48%) were classified with Grade III, 26 patients (14%) were classified with Grade IV and 3 patients (2%) were classified with Grade V. This difference may be due to the fact that this study included a small number of patients.
In this current study, it was found that 90% of the patients were complaining of wheezes and 10% of cases have silent chest. On the contrary, Schols et al. [45] stated wheezing and chest tightness are nonspecific symptoms that may vary between days and over the course of a single day. Alternatively, widespread inspiratory or expiratory wheezes can be present on listening to the chest.
COPD often coexists with other disease. (Co morbidities) that may have a significant impact on prognosis. It is increasingly recognized that many patients with COPD have co morbidities that have a major impact on quality of life and survival. Co morbidities are common at any severity of COPD [46] .
The current study revealed that the most common co morbidities in COPD patients were respiratory infections (53.9%), heart failure (44.5%), IHD (37.9%), AF (30.5%), HTN (26.9%) and DM (19.5%) respectively. In accordance with our study, Benfield et al. [47] found that serious infections, especially respiratory infections, are the most frequently seen in patients with COPD. Soriano et al. [48] and Fabbri et al. [49] reported that CVD is a major co morbidity in COPD, 4 separate entities within CVD will be considered: ischemic heart disease, heart failure, atrial fibrillation and hypertension. On the contrary, Mikkelsen [50] . found that COPD is a disease with multiple co-morbidities and the most common comorbidities of COPD are anxiety and depression. Fabbri et al. [49] reported that Hypertension is likely to be the most frequently occurring co morbidity in COPD and has implications on prognosis. Also, there is a different result concluded by Rubinsztajn and Chazan [51] in their study of hospitalized observed COPD patients from the national hospital discharge survey, in the United States from 1979 to 2001. They reported that the most common co morbidities were pneumonia, hypertension, diabetes, heart failure, ischemic heart disease, pulmonary vascular disease, thoracic malignancy and respiratory failure respectively. Soriano et al. [48] in their study of COPD patients (n = 2699) reported that the most common co morbidities were pneumonia, osteoporosis, respiratory infections, myocardial infarction, angina, bone fracture, glaucoma and cataract. In a study done by Graham Barr et al. [43] among 1003 patients with COPD, the most prevalent co morbid diseases were hypertension (55%), hypercholesterolemia (52%), depression (37%), cataracts (31%) and osteoporosis (28%). This difference between the present study and the above listed ones may be related to difference in the numbers of enrolled patients in each study and the difference in the communities in which the studies were conducted.
In the present study it was found that the most common complications in COPD patients were corpulmonale (44.5%), respiratory failure type II (16.6%), secondary polycythemia (15.1%), pneumothorax (10.7%), lung cancer (12.2%) and complications due to medications including DM (40.9%), HTN (52.4%), IHD (27.3%), Gastritis (12.2%), lung cancer (12.2%), osteoporosis (0.6%) and anxiety, irritability (3.1%). This matches with the study conducted by Mannino et al. [52] that shows that the presence of metabolic syndrome and manifest diabetes are more frequent in COPD.
Spirometry is the gold standard for COPD and is the only accurate method of measuring the degree of airflow obstruction in patients with COPD; it should be used in conjunction with a good history and physical examination. A diagnosis of airflow obstruction can be made if FEV1/FVC <70% and FEV1 <80% predicted normal values. In the present study, it was found that the studied cases had FEV1/FVC ranged from 30.2% À67.0 with a mean of 46.49 ± 8.14. So, according to GOLD guidelines, these studied cases were classified between moderate to severe COPD. This result differs from those reported by Steuten et al. [53] , who studied 317 patients with COPD according to GOLD guidelines, 29% of the patients had mild COPD, 48% moderate, 17% severe and 5% very severe. Also, in a study done by Stahl et al. [54] who enrolled 168 subjects with COPD from a representative sample of the general population in the northern Sweden using GOLD stages, it was found that FEV1/FVC was >80% in 81 patients, 79-50% in 68 patients and 49-30% in 10 patients and no patient had a value less than 30%. This difference may be related to the smaller number of patients in the previous studies and the different communities where the studies were conducted upon.
As regards bronchodilators pharmacotherapy in the present study, it was found that 90.9% of our studied cases used long acting B2 agonists (LABA), 90.7% used short acting B2 agonists (SABA). In accordance with our study ERS/ATS guidelines [55] and Hay and Stone [56] stated that short-acting bronchodilators can increase exercise capacity in COPD patients and are indicated for acute symptom control and treatment of exacerbation. Unlike short-acting b2 agonists, long-acting b2 agonists should not be used to control symptoms or to treat exacerbations (i.e. as a rescue medication) but are intended for maintenance therapy. As regards anticholinergics, 88.5% of our studied cases used anticholinergics. This is partially similar to the study of Sheldon et al. [57] which stated that anticholinergics appear more useful in the relief of symptoms in older patients or those with severe disease and a heavy smoking history.
In this current study, it was found that 77.9% of the studied cases used theophylline. Controversy remains about the exact effects of xanthine derivatives. They may act as non selective phosphodiesterase inhibitors, but have also been reported to have a range of non-bronchodilator actions, the significance of which is disputed [58] . Vassallo et al. [59] stated that Theophylline can be used as a third-line treatment in patients. The mechanism of action remains uncertain but their mode of action is thought to induce relaxation of the smooth muscle in the airways.
As regards corticosteroids, 93.7% of our studied cases used inhaled corticosteroids. Similarly, Spencer et al. [60] found that regular treatment with inhaled corticosteroids improves symptoms, lung function, quality of life, and reduces the frequency of exacerbations in COPD. Also, Sin et al. [61] study included randomized controlled trials that had follow up group of patients from 1980 to 2002 evaluating high value of use of long acting bronchodilators and inhaled corticosteroids in reducing exacerbations in patients with moderate to severe COPD .On the other hand, Singh et al. [62] and Yang et al. [63] found that regular treatment with inhaled corticosteroids does not modify the long-term decline of FEV1 nor mortality in patients with COPD. Corticosteroids can produce a small increase in post bronchodilator FEV1 and a small reduction in bronchial reactivity in stable COPD. This difference may be attributed to the different number of enrolled patients in each study and difference in the community where the studies were conducted.
As regards antibiotics in this current study, 90.8% of the studied cases used broad spectrum antibiotics This is in contrast to what was concluded by Francis et al. [64] and Fletcher et al. [65] , who stated that continuous use of antibiotics was shown to have no effect on the frequency of exacerbations in COPD.
Regarding mucolytics, 90.8% of our subject studies used mucolytics. The regular use of mucolytics in COPD has been evaluated in a number of long-term studies with controversial results. National Institute for Clinical Excellence (NICE) [66] and Celli and MacNee [67] , showed that although a few patients with viscous sputum may benefit from mucolytics, the overall benefits seem to be very small.
Regarding non pharmacological treatment in the present study, it was found that 72.8% received pulmonary rehabilitation. The principal goals of pulmonary rehabilitation are to reduce symptoms, improve quality of life, and increase physical and emotional participation in everyday activities. [68, 69] . This result matches with that reported by ERS/ATS guidelines [55] which stated that pulmonary rehabilitation is a multidisciplinary program that is individually tailored and designed to optimize each patient's physical performance and psychological wellbeing.
In the present study, it was found that only 2.1% received pneumococcal vaccine. This matches with the study of Davis [70] conducted upon 100 patients with COPD who received pneumococcal vaccine but they found that there is no significance of pneumococcal vaccine in prevention of pneumonia. On the contrary, Leech et al. [71] found that there is a high significance in prevention of pneumonia in 189 COPD patients, though only one documented case of pneumococcal sepsis occurred in a patient who received pneumococcal vaccine and had pneumonia. Lee et al. [72] supported the value of pneumococcal vaccine in COPD patients through a study of 16,074 subjects (average age of 65 years) in the period from 1997 to 1998 and identification of pneumococcal pneumonia and all pneumonia related hospitalization in the period before and after vaccination. Similarly, Jackson et al. [73] and Alfageme et al. [74] stated that pneumococcal polysaccharide vaccine is recommended for COPD patients 65 years and older, and also in younger patients with significant co morbid conditions such as cardiac disease. In addition, this vaccine has been shown to reduce the incidence of community-acquired pneumonia in COPD patients younger than age 65 with an FEV1 <40% predicted.
As regards O 2 therapy in the acute setting (in the hospital), there was a highly significant relation between the presence of respiratory failure type 2, corpulmonale, pneumothorax, lung cancer and polycythemia as complications of COPD and the need for O 2 therapy. In accordance with our study, ERS/ATS guidelines [55] stated that O 2 therapy prevents tissue hypoxia by maintaining arterial oxygen saturation (SaO 2 ) at >90%. Also, Stoller et al. [75] demonstrated the benefits of short duration, intermittent supplemental O 2 in relief of breathlessness. On the same path, Standiford [76] mentioned that the primary goal of oxygen therapy is to maintain vital organ function by ensuring adequate oxygen delivery. This is achieved by increasing the baseline PaO 2 to at least 60 mmHg (or SaO 2 to at least 90%) at rest.
As regards assisted ventilation in the present study, 19.4% of the patients were put on non invasive mechanical ventilation (CPAP) and 11.9% were put on invasive mechanical ventilation. Non-invasive ventilation (NIV) is increasingly used in patients with stable very severe COPD [77] . There was a highly significant relation between the presence of respiratory failure type II and the need for CPAP (51.4%), while this relation was not significant with the rest of complications. The above result is supported by the study of Shiveraman et al. [78] , which showed that the mask of CPAP significantly improved gas exchange in seven patients with acute hypercapnic respiratory failure. The NICE guidelines [79] recommend the use of NIV as a treatment for chronic hypercapnic ventilatory failure in selected patients. ERS/ATS guidelines [55] stated that non invasive positive pressure ventilation (NPPV) should be offered to patients with exacerbations when, after optimal medical therapy and oxygenation, respiratory acidosis (pH < 7.36) and or excessive breathlessness persist. International Consensus Conferences in Intensive Care Medicine [80] mentioned that mechanical ventilation, either ''invasive'' or'' non-invasive'', is not a therapy but it is a form of life support until the cause underlying the acute respiratory failure is reversed with medical therapy.
In this current study, the mortality rate among the patients who were put on CPAP was 85.1%. This result does not match with that of Conti et al. [81] and Plant et al. [82] , who found that one-year mortality was reported to be lower in patients receiving NPPV for exacerbations of COPD, as compared to both conventional mechanical ventilation and optimal medical therapy alone. This difference might be due to the difference in the number of the patients enrolled in each study, as well as, the experience of the physicians about CPAP.
Regarding ICU admission, 31.6% of the cases were admitted to the ICU and 68.4% of them were not. This is partially similar with the finding of Skilbeck et al. [83] who stated that in a recent study of patients with COPD or lung cancer in the US Veterans Affairs Health System found that patients with COPD were much more likely to be admitted to an ICU, and have greater lengths of stay in the ICU during their terminal hospitalization, than patients with lung cancer. In the same study, significant geographic variation in ICU utilization was found for patients with COPD. Although variation in care may be influenced by many factors including availability, access and reimbursement issues, such geographic variation suggests a lack of consensus concerning the best approach to palliative and end-of-life care for patients with COPD. In summary, there are important opportunities for research and quality improvement if better palliative and end-of-life care is to be provided for patients with severe COPD.
As regards the burden of COPD, WHO [84] showed that the burden of COPD continues to increase, with recent statistics reporting that COPD affects the lives of 210 million people and contributes to 5% of deaths globally. Further evidence suggests that by 2030, COPD will become the 3rd leading cause of death worldwide. In the present study, the overall mortality rate among the studied patients was 5.7% and 8.5% among the patients who received O 2 therapy, 63.8% among the patients who were put on invasive mechanical ventilation and 44.7% among the patients who were admitted to the ICU. In accordance with our study, McGarvey et al. [85] mentioned that COPD is the fourth leading cause of death in the United States. In terms of COPD as the underlying cause of death, absolute mortality rates for patients aged 25 years or older were 77.3 deaths per 100,000 males and 56.0 deaths per 100,000 overall. Internationally, overall mortality rates from COPD vary markedly; it is more than 400 deaths per 100,000 populations in Japan. Also, Chapman et al. [86] reported that COPD is the fourth leading cause of death in the United States, affecting 32 million adults. It is also the sixth leading cause of death worldwide. National Heart, lung, and Blood institute [87] stated the age-adjusted death rates for COPD by race and sex in the US from 1960 to 1996, revealed that COPD death rates are very low among people under the age of 45 years, but then increase with age, and COPD becomes the fourth or fifth leading cause of death among those over 45 years, a pattern that reflects the cumulative effect of cigarette smoking, and also, the seventh leading cause of DALYs lost worldwide in 2030. In 2000, the WHO estimated 2.74 million deaths worldwide from COPD.
The International Bank for Reconstruction on and Development/The World Bank reported in 1990, COPD was ranked 12th as a burden of disease; by 2020 it is projected to rank 5th. More than 3 million COPD deaths will occur in 2005.On the same side, Bourke [15] estimated that the total deaths from COPD are projected to increase by more than 30% in the next 10 years. It is a major cause of morbidity and mortality. Worldwide, COPD causes about 3 million deaths each year. In the UK in 1999, the number of deaths from COPD had risen to 32, 155 [88] , which relates to one in 20 of all deaths, making it the 5th leading cause of death [89] . By the year 2020, COPD is expected to be third in the rankings for the global impact of disease scale [90] . In England and Wales, mortality appears to be greater in urban areas, with a particularly strong association with lower social class and poverty and higher smoking rates in this group.
Conclusions
1. If COPD cases are reduced, the quality of life for many people will increase substantially. There will also be more money available for healthcare that would have been previously been spent toward COPD cases. The benefits of fighting COPD are of great magnitude, and not one more day should go by without action being taken to prevent this disease from taking hold of another life. 2. COPD poses a common, growing and significant clinical challenge for patients and clinicians' expert knowledge regarding diagnosis and management can enhance patients' longevity and quality of life. Results of emerging studies will likely lead to enhancement in current management and new paradigms in managing patients with COPD.
Recommendations
1.
Smoking cessation is the single most important intervention to slow the rate of lung decline and reduce respiratory symptoms regardless of the severity of the patient's disease. The benefit of smoking cessation on the natural history of COPD is greater the earlier in the disease that cessation is achieved. 2. Also, preventive care focuses on avoiding irritants that can aggravate COPD. The most common ''triggers'' are smoking, second hand smoke, occupational fumes and chemicals, indoor air pollution (e.g. cooking with biomass fuels), outdoor air pollution, and infection. 3. Patient education also improves patient response to exacerbations. Prospective end-of-life discussions help patients understand advanced directives and therapies at end-of-life. Smoking cessation should be encouraged at each visit. The combination of pharmacologic and psychosocial treatment for smoking cessation has been shown to be superior to psychosocial treatment alone in patients with COPD. 4. Disease management involves partnering with nurses and respiratory therapists to assist in patient education and compliance. Patients enrolled in pulmonary rehabilitation receive instruction in self. 5. Patients with COPD are at increased risk for complications from pulmonary infections (e.g. hospitalization, increased use of antibiotics). Therefore, the CDC Advisory Committee of Immunization Practices recommends all patients receive pneumococcal polysaccharide vaccine and yearly influenza vaccine. 6. Early outpatient pulmonary rehabilitation after hospitalization is safe and results in significant improvements in exercise capacity and health status at 3 months. There is a pressing need to develop drugs that control symptoms and prevent the progression of COPD. Some progress has been made and there are several classes of drugs that are now in preclinical and clinical development for use in patients with COPD. 7. Longitudinal studies demonstrating the course of COPD are needed in a variety of populations exposed to various risk factors. Such studies would provide insight into the pathogenesis of COPD, identify additional genetic bases for COPD, and identify how genetic risk factors interact with environmental risk factors in specific patient populations. Factors that determine why some, but not all, smokers develop COPD need to be identified.
8. While spirometry is recommended to assess and monitor COPD, other measures need to be developed and evaluated in clinical practice. Reproducible and inexpensive exercise-testing methodologies (e.g. stair-climbing tests) suitable for use in developing countries need to be evaluated and their use encouraged. Spirometers need to be developed that can ensure economical and accurate performance when a relatively untrained operator administers the test. 9. Because COPD is not fully reversible and slowly progressive, it will become ever more important to identify early cases as more effective therapies emerge. Consensus on standard methods for detection and definition of early disease needs to be developed. Data to show whether or not screening spirometry is effective in directing management decisions in COPD outcomes are required. 10. The specific components of effective education for patients with COPD need to be determined. It is not known, for example, whether patients with COPD should be given an individual management plan, or whether these plans are effective in reducing health care costs or improving the outcomes of exacerbations. Developing and evaluating effective tools for physician education concerning prevention, diagnosis, and management of COPD will be important in view of the increasing public health problem presented by COPD.
